Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

77
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
77
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

201
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
201
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

46
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
46
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.3K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.3K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

63
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
63
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parallel Optimal Calibration of Mixed-Format Items for Achievement Tests.

Psychometrika·2026
Same author

Optimal Item Calibration in the Context of the Swedish Scholastic Aptitude Test.

Applied psychological measurement·2026
Same author

Parallel Optimal Calibration of Mixed-Format Items for Achievement Tests.

Psychometrika·2024
Same author

Optimal Item Calibration for Computerized Achievement Tests.

Psychometrika·2019
Same author

Approaches to sample size calculation for clinical trials in rare diseases.

Pharmaceutical statistics·2018
Same journal

Comparison of Different Methods for the Meta-Analysis of Diagnostic Test Accuracy Studies-A Simulation Study.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

Related Experiment Video

Updated: Nov 9, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.3K

Optimal dose-finding for efficacy-safety models.

Renata Eirini Tsirpitzi1, Frank Miller1

  • 1Department of Statistics, Stockholm University, Stockholm, Sweden.

Biometrical Journal. Biometrische Zeitschrift
|April 8, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for drug dose-finding, balancing efficacy and safety using a clinical utility index. The approach optimizes experimental designs to find the best dose for patient benefit.

Keywords:
Elfving's methodbivariate modeldose-findingoptimal designsequential design

More Related Videos

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.8K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.1K

Related Experiment Videos

Last Updated: Nov 9, 2025

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

5.3K
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.8K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.1K

Area of Science:

  • Pharmacometrics
  • Clinical Trial Design
  • Biostatistics

Background:

  • Dose-finding studies are crucial for new drug development, aiming to identify optimal doses based on efficacy and safety.
  • Existing optimal experimental designs often prioritize efficacy, potentially neglecting safety considerations.
  • Balancing efficacy and safety is essential for determining a drug's therapeutic potential.

Purpose of the Study:

  • To develop and evaluate an experimental design method that balances drug efficacy and safety.
  • To determine the optimal dose by maximizing patient clinical utility.
  • To address limitations of efficacy-focused designs in dose-finding studies.

Main Methods:

  • Utilized a simplified bivariate Emax model for efficacy-safety assessment.
  • Employed the clinical utility index to quantify the balance between efficacy and safety.
  • Applied a multivariate version of Elfving's method to derive locally -optimal designs.
  • Proposed a sequential design to handle parameter dependencies.

Main Results:

  • Derived an algebraic solution for -optimal designs.
  • Identified the expected therapeutic index as a critical factor influencing optimal design parameters (number of doses, dose levels, weights).
  • Demonstrated the proposed sequential design's effectiveness through a simulation study.

Conclusions:

  • The proposed method provides an effective approach for dose-finding by optimizing clinical utility.
  • The expected therapeutic index is a key determinant for designing efficient dose-finding studies.
  • The sequential design offers a practical solution for parameter-dependent optimal designs in drug development.